SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/52426 |
Resumo: | A Rede Genômica Fiocruz é formada por especialistas de todas as unidades da Fundação no país e de institutos parceiros que se empenham diariamente em gerar dados mais robustos sobre o comportamento do SARS-Cov-2 e contribuir para um melhor preparo do país no enfrentamento da pandemia em termos de diagnóstico mais precisos e vacinas eficazes. Saiba mais sobre a Rede Genômica Fiocruz em: http://www.genomahcov.fiocruz.br/ |
| id |
CRUZ_b341f7a6b1fcca27beb860c4e8071830 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/52426 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Dejnirattisai, WanwisaHuo, JiandongZhou, DamingZahradník, JiríSupasa, PiyadaLiu, ChangDuyvesteyn, Helen M.E.Ginn, Helen M.Mentzer, Alexander J.Tuekprakhon, AekkachaiNutalai, RungtiwaWang, BeibeiDijokaite, AisteKhan, SumanAvinoam, OriBahar, MohammadSkelly, DonalAdele, SandraJohnson, Sile AnnAmini, AliRitter, Thomas G.Mason, ChrisDold, ChristinaPan, DanielAssadi, SaraBellass, AdamOmo-Dare, NicolaKoeckerling, DavidFlaxman, AmyJenkin, DanielAley, Parvinder K.Voysey, MerrynClemens, Sue Ann CostaNaveca, Felipe GomesNascimento, ValdineteNascimento, FernandaCosta, Cristiano Fernandes daResende, Paola CristinaPauvolid-Correa, AlexSiqueira, Marilda M.Baillie, VickySerafin, NataliKwatra, GauravSilva, Kelly daMadhi, Shabir A.Nunes, Marta C.Malik, TariqOpenshaw, Peter J. M.Baillie, J. KennethSemple, Malcolm G.Townsend, Alain R.Huang, Kuan-Ying A.Tan, Tiong KitCarroll, Miles W.Klenerman, PaulBarnes, EleanorDunachie, Susanna J.Constantinides, BedeWebster, HermioneCrook, DerrickPollard, Andrew J.Lambe, TeresaOPTIC ConsortiumISARIC4C ConsortiumPaterson, Neil G.Williams, Mark A.Hall, David R.Fry, Elizabeth E.Mongkolsapaya, JuthathipRen, JingshanSchreiber, GideonStuart, David I.Screaton, Gavin R.2022-04-26T19:52:54Z2022-04-26T19:52:54Z2022DEJNIRATTISAI, Wanwisa et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell Press Open Access, v. 185, p. 467-484, 2022.https://www.arca.fiocruz.br/handle/icict/5242610.1016/j.cell.2021.12.046A Rede Genômica Fiocruz é formada por especialistas de todas as unidades da Fundação no país e de institutos parceiros que se empenham diariamente em gerar dados mais robustos sobre o comportamento do SARS-Cov-2 e contribuir para um melhor preparo do país no enfrentamento da pandemia em termos de diagnóstico mais precisos e vacinas eficazes. Saiba mais sobre a Rede Genômica Fiocruz em: http://www.genomahcov.fiocruz.br/A Variante de Preocupação Ômicron (B.1.1.529) trouxe uma grande expansão mundial dos contágios pelo SARS-CoV-2, mesmo em países onde a imunização contra o vírus já estava avançada. Para compreender como a coleção de mutações da Glicoproteína S da Ômicron leva ao escape da resposta imunológica, um esforço internacional de pesquisa que incluiu cientistas da Rede Genômica Fiocruz analisou as estruturas de proteínas, além da neutralização da capacidade de causar infecção ao expôr amostras da Ômicron a diferentes preparados contendo anticorpos como: 1) o soro de pacientes infectados com outras amostras do vírus, 2) os chamados “anticorpos monoclonais” selecionados em laboratório, e 3) o soro de pessoas vacinadas.O presente artigo, fruto desta colaboração para o estudo de múltiplos fatores envolvidos no escape da resposta imune apresentado pela Ômicron, demonstrou que a nova variante é quase 17 vezes mais resistente à neutralização pelos anticorpos gerados em resposta a uma linhagem da primeira onda da pandemia. O estudo mostra ainda que um esquema vacinal de três doses aumenta consideravelmente a resposta ao vírus, incluindo a neutralização da variante Ômicron, que não era suficiente apenas com duas doses do imunizante. O artigo mostra ainda que a estrutura de porções da Glicoproteína S da Ômicron estão envolvidas em “compensar” a ação de anticorpos através de uma ligação mais forte à ACE2, molécula que atua como receptor viral nas células humanas.On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK / Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK.Oxford University Hospitals NHS Foundation Trust, Oxford, UK.Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.Translational Gastroenterology Unit, University of Oxford, Oxford, UK.NIHR Oxford Biomedical Research Centre, Oxford, UK.Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.Department of Respiratory Sciences, University of Leicester, Leicester, UK.Medical Sciences Division, University of Oxford, Oxford, UK.Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.Institute of Global Health, University of Siena, Siena, Brazil.Fundação Oswaldo Cruz. Fiocruz Amazônia - Instituto Leônidas e Maria Deane. Laboratório de Ecologia de Doenças Transmissíveis na Amazônia. Manaus, Amazonas, Brasil.Fundação de Vigilância em Saúde do Amazonas. Manaus, Amazonas, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de vírus respiratórios. Rio de Janeiro, RJ, Brasil.Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.engCell Press JournalCoronavirus InfectionsCOVID-19COVID-19SARS-CoV-2Rede Genômica FiocruzGENOMAHCOVSARS-CoV-2Omicron-B.1.1.529Neutralizing antibody responsesInfecções por CoronavirusCOVID-19SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responsesinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/52426/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALSARS-CoV-2 Omicron-B_1_1_529.pdfSARS-CoV-2 Omicron-B_1_1_529.pdfapplication/pdf12632109https://www.arca.fiocruz.br/bitstream/icict/52426/2/SARS-CoV-2%20Omicron-B_1_1_529.pdf4281f9b3fdc0643ef0c9609551039bfaMD52_AUTORIZACAO_DEPOSITO_ARCA_REDE_GENOMICA.pdf_AUTORIZACAO_DEPOSITO_ARCA_REDE_GENOMICA.pdfapplication/pdf134844https://www.arca.fiocruz.br/bitstream/icict/52426/3/_AUTORIZACAO_DEPOSITO_ARCA_REDE_GENOMICA.pdf28ef5cd96257018f624857e2ce8ab529MD53icict/524262022-07-18 16:00:41.111oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-07-18T19:00:41Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| title |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| spellingShingle |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses Dejnirattisai, Wanwisa Coronavirus Infections COVID-19 COVID-19 SARS-CoV-2 Rede Genômica Fiocruz GENOMAHCOV SARS-CoV-2 Omicron-B.1.1.529 Neutralizing antibody responses Infecções por Coronavirus COVID-19 |
| title_short |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| title_full |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| title_fullStr |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| title_full_unstemmed |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| title_sort |
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses |
| author |
Dejnirattisai, Wanwisa |
| author_facet |
Dejnirattisai, Wanwisa Huo, Jiandong Zhou, Daming Zahradník, Jirí Supasa, Piyada Liu, Chang Duyvesteyn, Helen M.E. Ginn, Helen M. Mentzer, Alexander J. Tuekprakhon, Aekkachai Nutalai, Rungtiwa Wang, Beibei Dijokaite, Aiste Khan, Suman Avinoam, Ori Bahar, Mohammad Skelly, Donal Adele, Sandra Johnson, Sile Ann Amini, Ali Ritter, Thomas G. Mason, Chris Dold, Christina Pan, Daniel Assadi, Sara Bellass, Adam Omo-Dare, Nicola Koeckerling, David Flaxman, Amy Jenkin, Daniel Aley, Parvinder K. Voysey, Merryn Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid-Correa, Alex Siqueira, Marilda M. Baillie, Vicky Serafin, Natali Kwatra, Gaurav Silva, Kelly da Madhi, Shabir A. Nunes, Marta C. Malik, Tariq Openshaw, Peter J. M. Baillie, J. Kenneth Semple, Malcolm G. Townsend, Alain R. Huang, Kuan-Ying A. Tan, Tiong Kit Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Constantinides, Bede Webster, Hermione Crook, Derrick Pollard, Andrew J. Lambe, Teresa OPTIC Consortium ISARIC4C Consortium Paterson, Neil G. Williams, Mark A. Hall, David R. Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Schreiber, Gideon Stuart, David I. Screaton, Gavin R. |
| author_role |
author |
| author2 |
Huo, Jiandong Zhou, Daming Zahradník, Jirí Supasa, Piyada Liu, Chang Duyvesteyn, Helen M.E. Ginn, Helen M. Mentzer, Alexander J. Tuekprakhon, Aekkachai Nutalai, Rungtiwa Wang, Beibei Dijokaite, Aiste Khan, Suman Avinoam, Ori Bahar, Mohammad Skelly, Donal Adele, Sandra Johnson, Sile Ann Amini, Ali Ritter, Thomas G. Mason, Chris Dold, Christina Pan, Daniel Assadi, Sara Bellass, Adam Omo-Dare, Nicola Koeckerling, David Flaxman, Amy Jenkin, Daniel Aley, Parvinder K. Voysey, Merryn Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid-Correa, Alex Siqueira, Marilda M. Baillie, Vicky Serafin, Natali Kwatra, Gaurav Silva, Kelly da Madhi, Shabir A. Nunes, Marta C. Malik, Tariq Openshaw, Peter J. M. Baillie, J. Kenneth Semple, Malcolm G. Townsend, Alain R. Huang, Kuan-Ying A. Tan, Tiong Kit Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Constantinides, Bede Webster, Hermione Crook, Derrick Pollard, Andrew J. Lambe, Teresa OPTIC Consortium ISARIC4C Consortium Paterson, Neil G. Williams, Mark A. Hall, David R. Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Schreiber, Gideon Stuart, David I. Screaton, Gavin R. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Dejnirattisai, Wanwisa Huo, Jiandong Zhou, Daming Zahradník, Jirí Supasa, Piyada Liu, Chang Duyvesteyn, Helen M.E. Ginn, Helen M. Mentzer, Alexander J. Tuekprakhon, Aekkachai Nutalai, Rungtiwa Wang, Beibei Dijokaite, Aiste Khan, Suman Avinoam, Ori Bahar, Mohammad Skelly, Donal Adele, Sandra Johnson, Sile Ann Amini, Ali Ritter, Thomas G. Mason, Chris Dold, Christina Pan, Daniel Assadi, Sara Bellass, Adam Omo-Dare, Nicola Koeckerling, David Flaxman, Amy Jenkin, Daniel Aley, Parvinder K. Voysey, Merryn Clemens, Sue Ann Costa Naveca, Felipe Gomes Nascimento, Valdinete Nascimento, Fernanda Costa, Cristiano Fernandes da Resende, Paola Cristina Pauvolid-Correa, Alex Siqueira, Marilda M. Baillie, Vicky Serafin, Natali Kwatra, Gaurav Silva, Kelly da Madhi, Shabir A. Nunes, Marta C. Malik, Tariq Openshaw, Peter J. M. Baillie, J. Kenneth Semple, Malcolm G. Townsend, Alain R. Huang, Kuan-Ying A. Tan, Tiong Kit Carroll, Miles W. Klenerman, Paul Barnes, Eleanor Dunachie, Susanna J. Constantinides, Bede Webster, Hermione Crook, Derrick Pollard, Andrew J. Lambe, Teresa OPTIC Consortium ISARIC4C Consortium Paterson, Neil G. Williams, Mark A. Hall, David R. Fry, Elizabeth E. Mongkolsapaya, Juthathip Ren, Jingshan Schreiber, Gideon Stuart, David I. Screaton, Gavin R. |
| dc.subject.mesh.pt_BR.fl_str_mv |
Coronavirus Infections COVID-19 |
| topic |
Coronavirus Infections COVID-19 COVID-19 SARS-CoV-2 Rede Genômica Fiocruz GENOMAHCOV SARS-CoV-2 Omicron-B.1.1.529 Neutralizing antibody responses Infecções por Coronavirus COVID-19 |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 SARS-CoV-2 Rede Genômica Fiocruz GENOMAHCOV |
| dc.subject.en.pt_BR.fl_str_mv |
SARS-CoV-2 Omicron-B.1.1.529 Neutralizing antibody responses |
| dc.subject.decs.pt_BR.fl_str_mv |
Infecções por Coronavirus COVID-19 |
| description |
A Rede Genômica Fiocruz é formada por especialistas de todas as unidades da Fundação no país e de institutos parceiros que se empenham diariamente em gerar dados mais robustos sobre o comportamento do SARS-Cov-2 e contribuir para um melhor preparo do país no enfrentamento da pandemia em termos de diagnóstico mais precisos e vacinas eficazes. Saiba mais sobre a Rede Genômica Fiocruz em: http://www.genomahcov.fiocruz.br/ |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-04-26T19:52:54Z |
| dc.date.available.fl_str_mv |
2022-04-26T19:52:54Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
DEJNIRATTISAI, Wanwisa et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell Press Open Access, v. 185, p. 467-484, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/52426 |
| dc.identifier.doi.none.fl_str_mv |
10.1016/j.cell.2021.12.046 |
| identifier_str_mv |
DEJNIRATTISAI, Wanwisa et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell Press Open Access, v. 185, p. 467-484, 2022. 10.1016/j.cell.2021.12.046 |
| url |
https://www.arca.fiocruz.br/handle/icict/52426 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Cell Press Journal |
| publisher.none.fl_str_mv |
Cell Press Journal |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/52426/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/52426/2/SARS-CoV-2%20Omicron-B_1_1_529.pdf https://www.arca.fiocruz.br/bitstream/icict/52426/3/_AUTORIZACAO_DEPOSITO_ARCA_REDE_GENOMICA.pdf |
| bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 4281f9b3fdc0643ef0c9609551039bfa 28ef5cd96257018f624857e2ce8ab529 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009134552875008 |